News & Videos - ZOETIS INC. CLASS A - English

ZTS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Zoetis Inc. (NYSE: ZTS) Investors with Losses to Contact the Firm PR Newswire RADNOR, Pa., April 18, 2024 RADNOR, Pa. , April 18, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of Zoetis Inc. (NYSE: ZTS) ("Zoetis"). On April 12, 2024 , The Wall Street Journal published an article on...

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTS PR Newswire NEW YORK, April 18, 2024 NEW YORK , April 18, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zoetis Inc. (NYSE: ZTS) resulting from allegations that Zoetis may have issued materially misleading business information to the investing public. SO...

Scout Clean Energy Announces 12-Year Virtual Power Purchase Agreement with Zoetis Inc. PR Newswire BOULDER, Colo., April 18, 2024 BOULDER, Colo. , April 18, 2024 /PRNewswire/ -- Scout Clean Energy (Scout), a Colorado -based renewable energy developer-owner-operator, is pleased to announce they have signed a Virtual Power Purchase Agreement (VPPA) with Zoetis Inc. for a 50-megawatt (MW) portion of Scout's operating Heart of Texas Wind Farm. This constitutes more than one-fourth of the total...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm PR Newswire LOS ANGELES, April 15, 2024 LOS ANGELES , April 15, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE: ZTS ) for violations of the securities laws. The investigation focuses on...

LOS ANGELES, CA / ACCESSWIRE / April 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Zoetis is the subject of an Investor's Business Daily report published on...

Zoetis, the world’s leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of a new building dedicated to diagnostics and biodevices research and development (R&D) to meet the needs of veterinarians, livestock farmers and pet owners. The expanded site will serve as the hub for Zoetis’ engineering and diagnostics work including device reliability testing. The new building features more than 78,000 square feet...

Zoetis, the world’s leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of a new building dedicated to diagnostics and biodevices research and development (R&D) to meet the needs of veterinarians, livestock farmers and pet owners. The expanded site will serve as the hub for Zoetis’ engineering and diagnostics work including device reliability testing. The new building features more than 78,000 square feet...

Zoetis: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230809927875/en/ Zoetis CEO Kristin Peck (center), cuts the ribbon, marking the official opening of the company's new monoclonal antibodies (mAbs) expansion. Ms. Peck is pictured with Zoetis leadership and local officials. Source: Zoetis NEWS FACTS Today, Zoetis, the world leader in Animal Health, marked the official opening of its new monoclonal antibodies (mAbs) expansion with a...

Zoetis, the world’s leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of our new monoclonal antibodies (mAbs) expansion, which will enable the site to increase production of products that control osteoarthritis pain in dogs and cats – our largest growing area of need for pet care customers. The site will also be a home for future innovation and serve as a Veterinary Medicine R&D registration facility for the...

Zoetis Inc . (NYSE:ZTS) today reported its financial results for the second quarter of 2023 and updated its guidance for full year 2023. The company reported revenue of $2.2 billion for the second quarter of 2023, an increase of 6% compared with the second quarter of 2022. On an operational 1 basis, revenue for the second quarter of 2023 increased 9% compared with the second quarter of 2022, excluding the impact of foreign currency. Net income for the second quarter of 2023 was $671 million, or...

Zoetis, the world’s leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of our new monoclonal antibodies (mAbs) expansion, which will enable the site to increase production of products that control osteoarthritis pain in dogs and cats – our largest growing area of need for pet care customers. The site will also be a home for future innovation and serve as a Veterinary Medicine R&D registration facility for the...

Zoetis Inc. (NYSE:ZTS) has been named to Fast Company’s list of Best Workplaces for Innovators for 2023 . Zoetis is the only stand-alone animal health company to be included on this year’s list which honors businesses that demonstrate a commitment to encouraging innovation at all levels. “Our innovative culture means we are always seeking to understand how we can meet our customers’ next unmet need,” said Rob Polzer, Executive Vice President and President, Research & Development. “As...

Zoetis Inc. (NYSE:ZTS) today announced the addition of Ester Banque as Executive Vice President and President, U.S. Operations, for the company, effective July 10, 2023. Ms. Banque is an accomplished global senior executive with over 30 years of experience in health sciences with top tier pharmaceutical companies. Ester will be a member of the Zoetis Executive team and report to Chief Executive Officer Kristin Peck. This press release features multimedia. View the full release here:...

Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Aug. 8, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations . Information on accessing and...

Zoetis today published its 2022 Sustainability Report “Together We Are Making a Difference for a Better World”, describing the company’s progress toward achieving its Driven to Care long-term sustainability aspirations and continued disclosure on environmental, social and governance (ESG) topics. The report highlights the company’s journey to advance sustainability in Animal Health for a better future through specific actions that support Communities, Animals and the Planet. These...

Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2023 Jaws and Paws Conference on Wednesday, May 31, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 3:35 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be...

Zoetis Inc. (NYSE:ZTS) is hosting an investor day at 9:00 a.m. ET today at the New York Stock Exchange, where the company will dive into its compelling growth ambitions, its innovative and robust R&D pipeline and its financial roadmap to continue delivering shareholder value, as it Shapes Animal Health for the Next Decade . During today’s presentations, Chief Executive Officer Kristin Peck, Chief Financial Officer Wetteny Joseph, President of Research & Development Robert Polzer, Ph.D., and...

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.375 per share for the third quarter of 2023. The dividend will be paid on Friday, September 1, 2023, to all holders of record of the Company’s common stock as of the close of business on Friday, July 21, 2023. About Zoetis As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent,...

Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs. Librela is the first and only once-monthly, anti-NGF monoclonal antibody treatment for canine OA pain and is approved as safe and effective in providing long-term control of OA pain symptoms in dogs, which can improve their mobility and overall quality of life. 1,2 The Unmet Need in Canine OA...

Zoetis Inc . (NYSE: ZTS) today reported its financial results for the first quarter of 2023 and maintained its guidance for full year 2023. The company reported revenue of $2.0 billion for the first quarter of 2023, an increase of 1% compared with the first quarter of 2022. On an operational 1 basis, revenue for the first quarter of 2023 increased 4% compared with the first quarter of 2022, excluding the impact of foreign currency. Net income for the first quarter of 2023 was $552 million, or...